Wei Wei*1, Xiao-Dong Ma†1, Guan-Min Jiang‡, Bin Shi§, Wen Zhong¶, Chun-Lei Sun§, Liang Zhao*, Yan-Jiao Hou*, Hao Wang*
Oncology Research, Vol.28, No.4, pp. 423-438, 2020, DOI:10.3727/096504020X15877284857868
Abstract Although oxaliplatin serves as one of the first-line drugs prescribed for treating colorectal cancer (CRC), the
therapeutic effect is disappointing due to drug resistance. So far, the molecular mechanisms mediating oxaliplatin resistance remain unclear. In this study, we found the chemoresistance in oxaliplatin-resistant HCT116 cells
(HCT116/OXA) was mediated by the upregulation of ERCC1 expression. In addition, the acquisition of resistance induced epithelial–mesenchymal transition (EMT) as well as the Slug overexpression. On the contrary,
Slug silencing reversed the EMT phenotype, decreased ERCC1 expression, and ameliorated drug resistance.
Further mechanistical studies revealed the enhanced Slug expression resulted More >